TY - JOUR
T1 - The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia
AU - Sumiyoshi, Tomiki
AU - Matsui, Mie
AU - Yamashita, Ikiko
AU - Nohara, Shigeru
AU - Kurachi, Masayoshi
AU - Uehara, Takashi
AU - Sumiyoshi, Sawako
AU - Sumiyoshi, Chika
AU - Meltzer, Herbert Y.
N1 - Funding Information:
This work was supported by the Japan Research Foundation for Clinical Pharmacology (TS) and grants from the Warren Foundation and the Test Family (HYM).
PY - 2001/5/15
Y1 - 2001/5/15
N2 - Background: The purpose of this study was to test the hypothesis that the addition of tandospirone, a 5-HT1A partial agonist, to ongoing treatment with typical antipsychotic drugs, would improve memory function in patients with schizophrenia. Methods: Eleven outpatients (male/female = 7/4) with schizophrenia who had been on stable doses of haloperidol and biperiden were given tandospirone, 30 mg/day, for 4 weeks. The Wechsler Memory Scale - Revised (WMS-R) was administered at baseline and 4 weeks after the addition of tandospirone. The Brief Psychiatric Rating Scale (BPRS; Total, Positive, and Negative subscale scores) and the Simpson-Angus Scale for Extrapyramidal Symptoms (SAS) were also completed on the two occasions. To exclude the possibility of a practice effect on the WMS-R test, 11 age-matched patients with schizophrenia (M/F = 7/4) were tested at baseline and after a 4-week interval. Results: Repeated measures analysis of variance revealed a significant time by group (patients with or without tandospirone) effect for the Verbal-, but not the Visual Memory composite scores of the WMS-R test; no significant change was observed in patients without tandospirone, whereas improvement in the Verbal Memory score was noted in patients receiving tandospirone. Moreover, there was improvement in the Inclusion score, an index of memory organization as measured by the Logical Memory subtest of WMS-R, only in patients with tandospirone. Scores on the BPRS and SAS were improved during treatment with tandospirone, but the effects did not reach statistical significance. Conclusions: The results suggest that adjunctive treatment with 5-HT1A agonists may improve some types of memory function in schizophrenia.
AB - Background: The purpose of this study was to test the hypothesis that the addition of tandospirone, a 5-HT1A partial agonist, to ongoing treatment with typical antipsychotic drugs, would improve memory function in patients with schizophrenia. Methods: Eleven outpatients (male/female = 7/4) with schizophrenia who had been on stable doses of haloperidol and biperiden were given tandospirone, 30 mg/day, for 4 weeks. The Wechsler Memory Scale - Revised (WMS-R) was administered at baseline and 4 weeks after the addition of tandospirone. The Brief Psychiatric Rating Scale (BPRS; Total, Positive, and Negative subscale scores) and the Simpson-Angus Scale for Extrapyramidal Symptoms (SAS) were also completed on the two occasions. To exclude the possibility of a practice effect on the WMS-R test, 11 age-matched patients with schizophrenia (M/F = 7/4) were tested at baseline and after a 4-week interval. Results: Repeated measures analysis of variance revealed a significant time by group (patients with or without tandospirone) effect for the Verbal-, but not the Visual Memory composite scores of the WMS-R test; no significant change was observed in patients without tandospirone, whereas improvement in the Verbal Memory score was noted in patients receiving tandospirone. Moreover, there was improvement in the Inclusion score, an index of memory organization as measured by the Logical Memory subtest of WMS-R, only in patients with tandospirone. Scores on the BPRS and SAS were improved during treatment with tandospirone, but the effects did not reach statistical significance. Conclusions: The results suggest that adjunctive treatment with 5-HT1A agonists may improve some types of memory function in schizophrenia.
KW - 5-HT agonist
KW - Cognitive function
KW - Memory organization
KW - Schizophrenia
KW - Verbal memory
KW - Wechsler Memory Scale - Revised
UR - http://www.scopus.com/inward/record.url?scp=0035873389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035873389&partnerID=8YFLogxK
U2 - 10.1016/S0006-3223(00)01025-8
DO - 10.1016/S0006-3223(00)01025-8
M3 - Article
C2 - 11343682
AN - SCOPUS:0035873389
SN - 0006-3223
VL - 49
SP - 861
EP - 868
JO - Biological psychiatry
JF - Biological psychiatry
IS - 10
ER -